ArticleEuropean heart journal. Cardiovascular Imaging2026
Does adding a delayed phase to cardiac computed tomography for coronary artery evaluation have prognostic value?
Article in European heart journal. Cardiovascular Imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging quantitative CCTA imaging biomarkers for cardiovascular risk stratification: a narrative review.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
13 authors.
Funding
Abstract
aimsCardiac computed tomography (CCT) assesses coronary anatomy and enables delayed-phase imaging, including extracellular volume fraction (ECV) for diffuse myocardial fibrosis and late iodine enhancement (LIE) for focal myocardial replacement fibrosis. ECV and LIE reflect distinct pathological processes; combining these measures may improve subclinical myocardial injury detection. This study evaluated LIE and ECV in patients undergoing CCT for coronary artery assessment and examined their association with clinical outcomes. The primary outcome was a composite of all-cause death and unplanned cardiovascular hospitalizations; the secondary outcome was cardiovascular events, defined as cardiac death and unplanned cardiovascular hospitalization. METHODS AND
resultsWe analysed 1207 consecutive patients who underwent CCT between January 2020 and September 2022. Patients were categorized into four groups based on the presence of LIE and elevated ECV. Associations with LIE and ECV, individually and combined, were assessed using Cox proportional hazards models. Of 1305 patients, 1207 met inclusion criteria and were followed for a mean of 26.0 ± 19.1 months. Kaplan-Meier analysis demonstrated a stepwise increase in risk across the four groups, with those having LIE and elevated ECV showing the highest cumulative incidence of composite events (log-rank P = 0.027). This group had increased risk for the composite outcome [hazard ratio (HR) 1.84, 95% confidence interval (CI) 1.22-2.79] and cardiovascular events (HR 2.67, 95% CI 1.32-5.41).
conclusionIn patients undergoing CCT for coronary artery evaluation, coexistence of LIE and elevated ECV is associated with higher risk of cardiovascular events and their assessment may provide synergistic prognostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.